Document is current
Any future updates will be listed below
-
Authors
Ramalingam, Harini https://orcid.org/0000-0001-7029-9069
Alvarez, Jesus
Flaten, Andrea
Cobo-Stark, Patricia https://orcid.org/0000-0002-8113-6211
Foster, Nicholas
Grilli, Elyse
Lakhia, Ronak https://orcid.org/0000-0002-4511-5341
Aboudehen, Karam
Carroll, Thomas https://orcid.org/0000-0002-8322-4928
Patel, Vishal https://orcid.org/0000-0003-2875-4659
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK102572)
- License Information
-
More Information
Article History
Received: 30 May 2024
Accepted: 9 May 2025
First Online: 28 May 2025
Competing interests
: V.P. has served as a scientific consultant for Otsuka Pharmaceuticals, Maze Therapeutics, Travere Therapeutics, and Regulus Therapeutics. V.P. serves as the chair of the Scientific Advisory Panel for the PKD Foundation. V.P. lab has a sponsored research agreement with Regulus Therapeutics, which is unrelated to this work. V.P. has licensed patents (US11168325B2) involving anti-miR-17 for the treatment of ADPKD (Inventors: John R. Androsavich, B. Nelson Chau, and Vishal D. Patel. Current Assignee: Regulus Therapeutics Inc. and University of Texas System), which is unrelated to the current manuscript. The remaining authors declare no competing interests.
